Eptacog alfa (Novo Nordisk)

N/A

Report date: 2022/04/24 18:00:01

Base Information

Drug NameEptacog alfa (Novo Nordisk)
Drug Alias Name依他凝血素α/重组凝血因子VIIarFVIIa (Novo Nordisk)Eptacog alpha/Coagulation Factor VIIa (Recombinant)Eptacog α/Coagulation Factor VIIa (Recombinant)Activated recombinant human factor VII +[15] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionCoagulation factor IX stimulantsCoagulation factor X stimulantsBlood coagulation pathway activation +[4] 
TargetsCoagulation factor IXCoagulation factor X
Therapy Area/IndicationsAcquired hemophiliaBurnsWounds and Injuries +[15] 
Global Approved IndicationsAcquired hemophiliaThrombastheniaHemophilia B +[5] 
Approved Indications in ChinaAcquired hemophiliaHemophilia BHemophilia A +[4] 
Original Approved Country/TerritoryEU
Original Approved Date1996/02/23
Country/TerritoryCzechiaBelgiumBulgaria +[39] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovo Nordisk A/S
China Registration ClassN/A

Develop Information

Active CompaniesNovo Nordisk A/S
Inactive CompaniesCanadian Institutes Of Health Research (Cihr)United States Army Institute Of Surgical ResearchFondazione Irccs Ca' Granda, Ospedale Maggiore Policlinico +[5] 
Active IndicationsAcquired hemophiliaThrombastheniaHemophilia B +[7] 
Inactive IndicationsBurnsWounds and InjuriesBlood Loss, Surgical +[8] 

Other Information

ATC CodeB02BD08
Related LinksWikipediaDrugBankKEGG